Skip to main content
Log in

Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment

  • Original Articles
  • Published:
Blut Aims and scope Submit manuscript

Summary

In an attempt to implement the small pool concept in Factor VIII purification, cryoprecipitate derived from heparinised plasma was reprecipitated in the cold providing a factor VIII concentrate for freeze drying and heat treatment. There was considerable purification; only 1% of the original plasma proteins was left in the final product. Factor VIII: C concentration was about 19 IU/ml. Factor VIII related antigen (RAg) appeared heterogeneous, with a broad base and asymmetry on crossed immunoelectrophoresis. Fibrinogen content was 15 g/l. In contrast to high-purity commercial concentrates, fibronectin was considerably concentrated. Immunoglobulin contents were similar to a high-purity commercial product. The amount of other plasma proteins was very small, varying from less than 0.2% for C 3 complement to 2.3% ceruloplasmin. In some respects the preparation may be considered as an intermediate-purity Factor VIII concentrate. Following addition of 2% sucrose before freeze drying, Factor VIII, total protein and fibrinogen remain virtually stable (less than 15% loss) during heating of the material to 60, 64 or 68°C for 24 to 72 h without changes of protein spectrum following heating. The heated product when stored at 4°C remains stable for at least 3 months. In two severe haemophiliacs receiving this heat treated product, in vivo Factor VIII recovery was 100% with a mean half life of 10.2 h.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bloom AL (1985) Physiological and clinical developments concerning factor VIII. In: Bowie EJW, Sharp AA (eds) Haemostasis and thrombosis. Butterworths, London

    Google Scholar 

  2. Smit Sibinga CTh, Welbergen H, Das PC, Griffin B (1981) High yield method of production of freeze dried purified factor VIII by blood banks. Lancet II: 449–450

    Google Scholar 

  3. Allain JP, Verroust F, Soulier JP (1980) In vitro characterization of factor VIII preparations. Vox Sang 38: 68–80

    Google Scholar 

  4. Spire B, Barre-Sinoussi F, Dormont D, Montagnier L, Chermann JC (1985) Inactivation of Lymphadenopathy-associated virus by heat, gamma rays and ultraviolet light. Lancet I: 188–189

    Google Scholar 

  5. Smit Sibinga CTh, Daenen SMG, Imhoff GW van, Maas A, Das PC (1984) Heparin small pool high yield factor VIII: in vivo recovery and half life of routinely produced freeze dried concentrate. Thromb Haemost 57: 12–15

    Google Scholar 

  6. Bodman J (1960) Agar gel starch block, starch gel and sponge rubber electrophoresis. In: Smith I (ed) Chromatographic and electrophoresis techniques. Heineman Medical Books, London

    Google Scholar 

  7. Clausen J (1969) Immunochemical téchniques for the identification and estimation of macromolecules. North Holland Publishing Company, Amsterdam

    Google Scholar 

  8. Laurell CB (1972) Electroimmunoassay. Scand J Clin Lab Invest 29 (Suppl 124): 34–44

    Google Scholar 

  9. Short PE, Williams CE, Picken AM, Hill FG (1982) Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci 39: 351–355

    Google Scholar 

  10. Grub AO (1983) Crossed immunoelectrophoresis. Scand J Immunol 17 (Suppl 10): 113–124

    Google Scholar 

  11. Barrowcliffe TW, Tydeman MS, Curtis AD, Thomas DP, Kirkwood TBL (1983) Factor VIII standardization. Lancet I: 62

    Google Scholar 

  12. Kirkwood TBL, Snape TJ (1980) Biometrics principle in clotting and clotlysis assays. Clin Lab Haematol 2: 155–167

    Google Scholar 

  13. Rock GA, Palmer DS, Tackaberry ES, Cruickshank WH (1978) The presence of high and low molecular weight forms of factor VIII in heparinised plasma. Thromb Res 13: 85–96

    Google Scholar 

  14. Morgenthaler J, Zuber T, Friedli H (1985) Influence of heparin and calcium chloride on assay, stability and recovery of factor VIII. Vox Sang 48: 8–17

    Google Scholar 

  15. Stathakis NE, Mosesson MW (1977) Interaction among heparin cold insoluble globulin and fibrinogen in formation of heparin precipitable fraction of plasma. J Clin Invest 60: 855–865

    Google Scholar 

  16. Mosher DF, Mosesson MW (1985) Plasma fibronectin: roles in haemostasis, macrophage function and related process. Water EJ, Sharp AA (eds). Butterworth, London

    Google Scholar 

  17. Rock GA, Smiley RK, Titley P, Palmer DS (1984) In vivo effectiveness of a high yield factor VIII concentrate prepared in a blood bank. N Engl J Med 311: 310–313

    Google Scholar 

  18. Nilsson IM, Hedner U (1977) Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br J Haematol 37: 543–557

    Google Scholar 

  19. Toolis F, MacKay G, Prowse CV (1980) In vivo characteristics of thaw syphon cryoprecipitate compared to other factor VIII preparations. Thromb Haemost 43: 25–27

    Google Scholar 

  20. Feldman F (1982) New developments in factor VIII purification, an overview. In: Smit Sibinga CTh, Das PC, Van Loghem JJ (eds) Blood transfusion and problems of bleeding. Martinus Nijhoff Publishers, The Hague

    Google Scholar 

  21. Reilly JT, McVerry BA, Mackie MJ (1983) Fibronectin in blood products an in-vitro and in-vivo study. J Clin Pathol 36: 1377–1381

    Google Scholar 

  22. Marrink J, Geest S v d, Sinnema R, Vellinga E, Vries EGE de (1985) Fibronectin complex (Fn-c) present in normal plasma. Thromb Res 37: 689–692

    Google Scholar 

  23. Reilly JT, Mackie MJ, McVerry BA (1984) Observations on the heterogeneity of fibronectin C. Thromb Res 33: 289–295

    Google Scholar 

  24. Levy JA, Mitra G, Wong MF, Mozen MM (1985) Inactivation by wet and dry heat for AIDS associated retrovirus during purification from plasma. Lancet I: 1456–1457

    Google Scholar 

  25. McDougal JS, Martin LS, Cort SP, Mozen MM, Heldebrout CM, Evatt BL (1985) Thermal inactivation of the acquired immunodeficiency virus, human T Lymphotropic virus III/Lymphadenopathy-associated virus with special reference to anti haemophilic factor. J Clin Invest 76: 875–877

    Google Scholar 

  26. Kernoff PBA, Miller EJ, Saudage GF, Machin SJ, Dewar MS, Preston FE (1985) wet heating for safer factor VIII concentrate. Lancet II: 721

    Google Scholar 

  27. Ellis BC, Stransky A (1961) A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 58: 477–478

    Google Scholar 

  28. McLeod AJ, Dickson IE, Foster PR (1983) Pasteurisation of coagulation factor concentrates. Thromb Haemost 50: 432 (abst 1371)

    Google Scholar 

  29. Quinnan GV, Wels MA, Wittek AE, Phelam UA, Mayher RE, Feinstone S, Purcell RH, Epstein JS (1986) Inactivation of human T-cell lymphotropic type III by heat, chemicals and irradiation. Transfusion 26: 481–483

    Google Scholar 

  30. Petricciani JC, McDougal JS, Evatt BL (1985) Case for concluding that heat treated licensed anti haemophiliac factor is safe from HTLV III. Lancet II: 890–891

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smit Sibinga, C., Schulting, P.J., Notebomer, J. et al. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment. Blut 56, 111–116 (1988). https://doi.org/10.1007/BF00320015

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00320015

Key words

Navigation